BioSpace

Details from Novartis’ failed cardiovascular trial offer ‘little silver lining’ for rivals

Full data from the Phase 3 HORIZON trial of Novartis' pelacarsen failed to show any apparent benefit, leading analysts to further reduce the odds of success for Lp(a)-lowering competitors such as Amgen’s olpasiran.

By BioSpace

1 min read
Details from Novartis’ failed cardiovascular trial offer ‘little silver lining’ for rivals
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights